Previous Close | 0.8678 |
Open | 0.8600 |
Bid | 0.8301 x 2200 |
Ask | 0.8810 x 1100 |
Day's Range | 0.8300 - 0.8998 |
52 Week Range | 0.4800 - 1.5200 |
Volume | |
Avg. Volume | 637,677 |
Market Cap | 90.246M |
Beta (5Y Monthly) | 1.96 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.6090 |
Earnings Date | Aug 05, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.25 |
Subscribe to Yahoo Finance Plus to view Fair Value for SEEL
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 12th Annual LifeSci Partners Corporate Access Event, to be held in San Francisco, California on January 9-11th, 2023.
Seelos Therapeutics Inc (NASDAQ: SEEL) announced in vivo data demonstrating that a single dose of SLS-004 downregulated the production of alpha-synuclein (α-synuclein). This reduction of α-synuclein by SLS-004 in an established α-synuclein overexpressing animal model of Parkinson's disease (PD) resulted in a substantial increase and recovery of degeneration in tyrosine hydroxylase positive (TH+) dopaminergic neurons. TH+ dopaminergic neurons in the midbrain region, called substantia nigra pars c
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced in vivo data demonstrating that a single dose of SLS-004 downregulated the production of alpha-synuclein (α-synuclein). This reduction of α-synuclein by SLS-004 in an established α-synuclein overexpressing animal model of Parkinson's disease (PD) resulted in substantial increase and recovery of degener